Diagnosis and classification of autoimmune hemolytic anemia.
Garrett F Bass, Emily T Tuscano, Joseph M Tuscano
https://pubmed.ncbi.nlm.nih.gov/24418298/Actively Recruiting
Led by Peking Union Medical College Hospital · Updated on 2025-08-08
22
Participants Needed
1
Research Sites
N/A
Total Duration
Warm autoimmune hemolytic anemia wAIHA is a rare disorder where the bodys immune system destroys its own red blood cells using warm or cold antibodies. The usual first treatment combines glucocorticoids with rituximab, but many patients either relapse or do not respond well. Other treatments include cyclosporine A, cyclophosphamide, rituximab alone, azathioprine, or splenectomy. Previous studies showed promising results with sirolimus for patients whose disease is hard to treat or has returned, so this trial explores sirolimuss effectiveness and safety for refractory or relapsed wAIHA. In this prospective trial, patients with refractory or relapsed primary wAIHA will receive oral sirolimus at doses of 1 to 3 mg per day, aiming for a blood concentration between 4 and 15 ngmL. Treatment is planned for at least six months. Patients who respond well will continue sirolimus for one more year before gradually reducing the dose. This approach hopes to provide a more accessible and affordable option for patients compared to other second-line therapies. Participants will be monitored over time to evaluate how well they respond to sirolimus at 3, 6, and 12 months, including the overall response rate and complete response rate. Researchers will also check for any treatment-related side effects, relapses, and other adverse events during this period. The study aims to improve quality of life and reduce complications like infections or cardiovascular events in patients with refractory or relapsed wAIHA. Total study involvement may last beyond one year depending on treatment response and follow-up needs.
CONDITIONS
Sirolimus in the Treatment of Refractory/Relapsed wAIHA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Peking Union Medical College Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - At least 6 months, continuing up to 1 year or more depending on response
Participants take sirolimus orally at 1-3 mg per day to treat refractory or relapsed warm autoimmune hemolytic anemia. Medication lasts at least 6 months, and responders continue treatment for 1 year followed by a gradual dose reduction.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Garrett F Bass, Emily T Tuscano, Joseph M Tuscano
https://pubmed.ncbi.nlm.nih.gov/24418298/Qi Wang, Ziwei Liu, Chen Yang...
https://pubmed.ncbi.nlm.nih.gov/42263666/Wilma Barcellini, Bruno Fattizzo, Anna Zaninoni...
https://pubmed.ncbi.nlm.nih.gov/25232059/Ulrich Jäger, Wilma Barcellini, Catherine M Broome...
https://pubmed.ncbi.nlm.nih.gov/31839434/Hongmin Li, Jiang Ji, Yali Du...
https://pubmed.ncbi.nlm.nih.gov/32771553/Quentin A Hill, Robert Stamps, Edwin Massey...
https://pubmed.ncbi.nlm.nih.gov/28005293/Wilma Barcellini, Bruno Fattizzo
https://pubmed.ncbi.nlm.nih.gov/33512406/Henrik Birgens, Henrik Frederiksen, Hans C Hasselbalch...
https://pubmed.ncbi.nlm.nih.gov/23981017/Karen L Bride, Tiffaney Vincent, Kim Smith-Whitley...
https://pubmed.ncbi.nlm.nih.gov/26504182/Peking Union Medical College Hospital
Lead Sponsor